Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives

Blood Adv. 2024 Feb 13;8(3):797-798. doi: 10.1182/bloodadvances.2023012068.

Authors

Sebastian G Wicha¹, Eva M A Wansing^{1

2

3}, Adrin Dadkhah^{2

3}, Francis A Ayuk³, Nicolaus M Kröger³, Claudia Langebrake^{2

3}

Affiliations

¹ Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.
² University Medical Center Hamburg-Eppendorf, Hospital Pharmacy, Hamburg, Germany.
³ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

No abstract available

Publication types

Letter
Comment

MeSH terms

Cell- and Tissue-Based Therapy
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen*
Vidarabine / analogs & derivatives*

Substances

Receptors, Chimeric Antigen
fludarabine
Receptors, Antigen, T-Cell
Vidarabine